<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30407821</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1520-4804</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>08</Day>                    </PubDate>                </JournalIssue>                <Title>Journal of medicinal chemistry</Title>                <ISOAbbreviation>J. Med. Chem.</ISOAbbreviation>            </Journal>            <ArticleTitle>Discovery of small molecule splicing modulators of survival motor neuron-2 (SMN2) for the treatment of Spinal Muscular Atrophy (SMA).</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.8b01291</ELocationID>            <Abstract>                <AbstractText>Spinal muscular atrophy (SMA), a rare neuromuscular disorder, is the leading genetic cause of death in infants and toddlers. SMA is caused by the deletion or a loss of function mutation of the survival motor neuron 1 (SMN1) gene. In humans, a second closely related gene SMN2 exists, however it codes for a less stable SMN protein. In recent years, significant progress has been made toward disease modifying treatments for SMA by modulating SMN2 pre-mRNA splicing. Herein, we describe the discovery of LMI070 / branaplam, a small molecule that stabilizes the interaction between the spliceosome and SMN2 pre-mRNA. Branaplam (1) originated from a high-throughput phenotypic screening hit, pyridazine 2, and evolved via multi-parameter lead optimization. In a severe mouse SMA model, branaplam treatment increased full-length SMN RNA and protein levels, and extended survival. Currently, branaplam is in clinical studies for SMA.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cheung</LastName>                    <ForeName>Atwood K</ForeName>                    <Initials>AK</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hurley</LastName>                    <ForeName>Brian</ForeName>                    <Initials>B</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Kerrigan</LastName>                    <ForeName>Ryan</ForeName>                    <Initials>R</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Shu</LastName>                    <ForeName>Lei</ForeName>                    <Initials>L</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Chin</LastName>                    <ForeName>Donovan N</ForeName>                    <Initials>DN</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Shen</LastName>                    <ForeName>Yiping</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>O'Brien</LastName>                    <ForeName>Gary</ForeName>                    <Initials>G</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Sung</LastName>                    <ForeName>Moo Je</ForeName>                    <Initials>MJ</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hou</LastName>                    <ForeName>Ying</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Axford</LastName>                    <ForeName>Jake</ForeName>                    <Initials>J</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Cody</LastName>                    <ForeName>Emma</ForeName>                    <Initials>E</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Robert</ForeName>                    <Initials>R</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Fazal</LastName>                    <ForeName>Aleem</ForeName>                    <Initials>A</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Tomlinson</LastName>                    <ForeName>Ronald C</ForeName>                    <Initials>RC</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Jain</LastName>                    <ForeName>Monish</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Deng</LastName>                    <ForeName>Lin</ForeName>                    <Initials>L</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hoffmaster</LastName>                    <ForeName>Keith</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Song</LastName>                    <ForeName>Cheng</ForeName>                    <Initials>C</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Van Hoosear</LastName>                    <ForeName>Mailin</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Shin</LastName>                    <ForeName>Youngah</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Servais</LastName>                    <ForeName>Rebecca</ForeName>                    <Initials>R</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Towler</LastName>                    <ForeName>Christopher S</ForeName>                    <Initials>CS</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hild</LastName>                    <ForeName>Marc</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Curtis</LastName>                    <ForeName>Daniel</ForeName>                    <Initials>D</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Dietrich</LastName>                    <ForeName>William F</ForeName>                    <Initials>WF</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Hamann</LastName>                    <ForeName>Lawrence G</ForeName>                    <Initials>LG</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Briner</LastName>                    <ForeName>Karin</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Karen S</ForeName>                    <Initials>KS</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Kobayashi</LastName>                    <ForeName>Dione</ForeName>                    <Initials>D</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Sivasankaran</LastName>                    <ForeName>Rajeev</ForeName>                    <Initials>R</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Dales</LastName>                    <ForeName>Natalie A</ForeName>                    <Initials>NA</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>08</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>J Med Chem</MedlineTA>            <NlmUniqueID>9716531</NlmUniqueID>            <ISSNLinking>0022-2623</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30407821</ArticleId>            <ArticleId IdType="doi">10.1021/acs.jmedchem.8b01291</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>